First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@article{Johnston2012FirstLineDT,
  title={First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis},
  author={J. Johnston and Tsz-Yin So},
  journal={Drugs},
  year={2012},
  volume={72},
  pages={1195-1211}
}
  • J. Johnston, Tsz-Yin So
  • Published 2012
  • Medicine
  • Drugs
  • Paediatric multiple sclerosis (MS) is defined as the onset of MS before the age of 18 years. Immunomodulatory disease-modifying therapies (i.e. the interferons [IFNs] and glatiramer acetate) are considered first-line treatments in adult patients with MS, but they are largely understudied in the paediatric population.IFNβ is a type 1 IFN produced by fibroblasts. The therapeutic effect achieved by IFNβ in MS is believed to be the result of a variety of mechanisms, including the inhibition of T… CONTINUE READING
    21 Citations
    The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data
    • 22
    Treatment of pediatric multiple sclerosis.
    • 4
    Multiple sclerosis: Therapeutic applications of advancing drug delivery systems.
    • 30
    Multiple Sclerosis: An Update.
    • 3
    • PDF
    The role of innate and adaptive immunity in Parkinson's disease.
    • 166
    • PDF
    Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis*
    • 29
    • PDF

    References

    SHOWING 1-10 OF 56 REFERENCES
    Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis
    • 126
    • Highly Influential
    Interferon beta-1a in children with multiple sclerosis is well tolerated.
    • 86
    • Highly Influential
    Therapeutic strategies in childhood multiple sclerosis
    • A. Ghezzi
    • Medicine
    • Therapeutic advances in neurological disorders
    • 2010
    • 27
    Treatment of pediatric multiple sclerosis and variants
    • 99
    • Highly Influential
    • PDF
    Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a: long-term results
    • 49
    Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    • 35
    • Highly Influential
    Randomized, comparative study of interferon β-1a treatment regimens in MS
    • 507
    • PDF
    Interferon-β1a for the treatment of multiple sclerosis
    • 56
    • Highly Influential